What do systematic reviews say?

Rituximab vs placebo

Rituximab as 'first choice' showed no clear difference in serious adverse events measured by clinical assessment over 28 months compared with placebo (low certainty).

• Rituximab for people with multiple sclerosis 2021 · Cochrane Headline outcomes only
  OR 1.25 [0.71, 2.2]
  1 study · 439 participants
  Low